AMZN
Amazon.com, Inc.
AMZN has lower modeled downside risk, despite its lower overall score.
EXPE
Expedia Group, Inc.
EXPE has the edge over AMZN overall, supported by stronger fundamentals and stronger valuation.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
EXPE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
EXPE's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over EXPE in the historical PE scenario, which offers more potential upside but is not a forecast.
EXPE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $261 | — |
| Current | 15x | $261 | — |
| Cheap | 19x | $330 | +26% |
| Fair | 25x | $428 | +64% |
| Expensive | 41x | $701 | +169% |
Historical ranges are pointers, not guarantees.
EXPE's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 11x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
EXPE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
EXPE has the edge over AMZN on the outlook, with more favorable valuation expectations.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over EXPE on earnings, with stronger typical year-over-year growth.
EXPE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.30 | +42% |
| Q3 2026 | $17.09 | +65% |
| Q2 2026 | $16.00 | +99% |
| Q1 2026 | $11.32 | +35% |
| Q4 2025 | $9.81 | +9.6% |
| Q3 2025 | $10.35 | +34% |
| Q2 2025 | $8.06 | +46% |
| Q1 2025 | $8.38 | +59% |
| Q4 2024 | $8.95 | +69% |
EXPE's earnings per share have climbed steadily: $17.09 over the past year, up 65% from the year before, and higher year over year for nine quarters in a row.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over EXPE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
EXPE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.9B | +12% |
| Q2 2026 | $4.3B | +14% |
| Q1 2026 | $3.4B | +15% |
| Q4 2025 | $3.5B | +11% |
| Q3 2025 | $4.4B | +8.7% |
| Q2 2025 | $3.8B | +6.4% |
| Q1 2025 | $3B | +3.4% |
| Q4 2024 | $3.2B | +10% |
EXPE's revenue has grown year over year for 22 quarters in a row: $4.9B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 27% | +3.4 points |
| Q2 2026 | 19% | +5.7 points |
| Q1 2026 | 7.3% | +9.7 points |
| Q4 2025 | 12% | +5.1 points |
| Q3 2025 | 23% | +4.7 points |
| Q2 2025 | 13% | +0.1 points |
| Q1 2025 | -2.3% | +1.5 points |
| Q4 2024 | 6.8% | +3.2 points |
EXPE has the edge over AMZN on profitability, with a higher operating margin.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
EXPE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4B | -$713M |
| Q2 2026 | $1.3B | +39% |
| Q1 2026 | $3.7B | +36% |
| Q4 2025 | $119M | +1600% |
| Q3 2025 | -$686M | +$1B |
| Q2 2025 | $921M | -30% |
| Q1 2025 | $2.8B | +2% |
| Q4 2024 | $7M | +$422M |
EXPE has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
EXPE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -272K shares |
| 1 year | -6.7% | -8.7M shares |
| 3 years | -17% | -25.5M shares |
| 5 years | -24% | -38.2M shares |
| Available history | -18% | -27.6M shares |
EXPE has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $669M |
| Q2 2026 | $270M |
| Q1 2026 | $788M |
| Q4 2025 | $327M |
| Q3 2025 | $531M |
| Q2 2025 | $688M |
| Q1 2025 | $384M |
| Q4 2024 | $198M |
EXPE spent $2.1B buying back its own shares over the past year, up 14% from the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
EXPE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 1.0x | Very low |
EXPE has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
EXPE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.3 | Neutral |
| Stochastic | 20.0 | Neutral |
EXPE's weekly RSI is 46 (neutral) and its Stochastic is 20 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
EXPE PE vs Consumer Cyclical Sector
| Metric | EXPE | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 18x | 15% below |
| PE % | 1 | 47 | 46 pts below |
EXPE has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over EXPE on trend strength, trading above more of its moving averages.
EXPE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $273.5 | 4.5% below |
| 20 week MA | $285.2 | 8.5% below |
| 50 week MA | $261.9 | 0.3% below |
| 100 week MA | $226.8 | 15% above |
| 200 week MA | $176.0 | 48% above |
EXPE has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 48% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over EXPE on returns for 2026, with the stronger performance.
EXPE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.3 | $127.0 | +17% |
| 2021 | $127.0 | $183.8 | +45% |
| 2022 | $183.8 | $86.4 | -53% |
| 2023 | $86.4 | $151.8 | +76% |
| 2024 | $151.8 | $186.1 | +23% |
| 2025 | $186.1 | $287.6 | +55% |
| 2026 YTD | $287.6 | $261.1 | -9.2% |
EXPE has finished higher in five of the last six years, two of them by more than 50%. It's down 9.2% so far in 2026.